89694-35-9 Usage
Uses
Used in Pharmaceutical Industry:
ETHYL 2,4,5-TRIOXOIMIDAZOLIDINE-1-ACETATE is used as a synthetic intermediate for the development of pharmaceutical compounds. Its unique structure and reactivity allow it to participate in various chemical reactions, facilitating the creation of new drugs with potential therapeutic applications.
Used in Agricultural Industry:
In the agricultural sector, ETHYL 2,4,5-TRIOXOIMIDAZOLIDINE-1-ACETATE is employed as a precursor in the synthesis of agrochemicals. Its ability to undergo multiple chemical transformations makes it suitable for the development of new pesticides, herbicides, or other agricultural chemicals that can enhance crop protection and yield.
Used in Chemical Industry:
ETHYL 2,4,5-TRIOXOIMIDAZOLIDINE-1-ACETATE is utilized as a key intermediate in the chemical industry for the production of various specialty chemicals. Its versatility in chemical reactions enables the synthesis of a wide range of compounds with diverse applications, such as solvents, dyes, or polymers.
Check Digit Verification of cas no
The CAS Registry Mumber 89694-35-9 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 8,9,6,9 and 4 respectively; the second part has 2 digits, 3 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 89694-35:
(7*8)+(6*9)+(5*6)+(4*9)+(3*4)+(2*3)+(1*5)=199
199 % 10 = 9
So 89694-35-9 is a valid CAS Registry Number.
InChI:InChI=1/C7H8N2O5/c1-2-14-4(10)3-9-6(12)5(11)8-7(9)13/h2-3H2,1H3,(H,8,11,13)
89694-35-9Relevant academic research and scientific papers
Highly selective aldose reductase inhibitors. 1. 3-(Arylalkyl)-2,4,5- trioxoimidazolidine-1-acetic acids
Ishii,Kotani,Nagaki,Shibayama,Toyomaki,Okukado,Ienaga,Okamoto
, p. 1924 - 1927 (2007/10/03)
A series of 3-(arylalkyl)-2,4,5-trioxoimidazolidine-1-acetic acids (1) was prepared and tested for aldose reductase (AR) and aldehyde reductase (ALR) inhibitory activities. These compounds showed strong inhibitory activity against AR without significant inhibitory activity for ALR. The ratio of IC50(ALR)IC50(AR) was > 1000 in some compounds. On the basis of pharmacological tests such as the recovery of reduced motor nerve conduction velocity and toxicological profile, 3-(3-nitrobenzyl)-2,4,5- trioxoimidazolidine-1-acetic acid (NZ-314) was selected as the candidate for clinical development.
